A Spanish foods giant has signed a licensing agreement to use OptiBiotix Health PLC’s (LON:OPTI) cholesterol and blood pressure-reducing LPLDL strain in some of its products.
The agreement gives Instituto Español de Nutrición Personalizada (IENP) non-exclusive rights to manufacture and market food supplements containing LPLDL in Spain for the next three years.
IENP is the precision nutrition branch of CAPSA Food, one of Spain’s largest food conglomerates which turns over more than €700mln a year.
READ: Opti sets launch date for weight management product
It has developed a test that analyses gut microbiome – the bacteria living in the intestine – which it then uses to place customers on different, targeted food supplement regimes to help get their microbiome back to healthy.
Under the terms of the deal, IENP will use its network to market the product in supermarkets, department stores, pharmacies, and online across Spain.
“We are delighted to enter the field of personalised and precision nutrition, one of the fastest-growing and highest-value sectors within the food industry,” said OptiBiotix’s business development director, Luis Gosálbez.
“Within two years of launch, we now have products being sold by numerous partners in over 30 countries around the world.
“We see this agreement as another step to growing revenues, market presence, and brand value of LPLDL, the 'Intel' inside a wide range of products in consumer and pharmaceutical markets around the world.”